Hypermethylation of P16 and DAPK Promoter Gene Regions in Patients with Non-invasive Urinary Bladder Cancer

Overview

Journal Arch Med Sci

Specialty General Medicine

Date 2012 Feb 2

PMID 22295037

Citations 22

Authors

Zbigniew Jablonowski

Edyta Reszka

Jolanta Gromadzinska

Wojciech Wasowicz

Marek Sosnowski

Affiliations

Soon will be listed here.

Abstract

Introduction: The aim of the study was to examine the frequency of methylation status in promoter regions of p16 and DAPK genes in patients with non-invasive bladder cancer.

Material And Methods: Forty-two patients (92.9% men, 73.8% smokers, 71.4% T1G1, 19.1% T1G2, 9.5% T1G3) and 36 healthy controls were studied. Isolation of genomic DNA from blood serum and methylation-specific PCR (MSP) were applied. Methylation status - methylated and unmethylated promoter regions of p16 and DAPK genes were analysed.

Results: Seventeen out of 42 patients (40.5%) had the methylated p16 gene, while methylation of the DAPK gene was seen in 27 of 42 cases (64.3%). In 12 patients (28.6%) both analysed genes were methylated. A statistically significant (p = 0.046) higher frequency of DAPK gene methylation (71.4%) was observed in patients with lower grade (G1) bladder cancer.

Conclusions: Detection of the aberrant hypermethylation of DAPK and p16 genes in blood DNA from non-invasive bladder cancer patients might offer an effective means for earlier auxiliary diagnosis of the malignancy.

Citing Articles

Diagnostic value of the combination of DAPK methylation in urinary sediment and B ultrasound for recurrent urinary bladder cancer.

Wang D, Qiu Z, Wu C World J Surg Oncol. 2023; 21(1):267.

PMID: 37626345 PMC: 10464327. DOI: 10.1186/s12957-023-03103-9.

Toward urinary cell-free DNA-based treatment of urothelial carcinoma: a narrative review.

Hayashi Y, Fujita K Transl Androl Urol. 2021; 10(4):1865-1877.

PMID: 33968675 PMC: 8100839. DOI: 10.21037/tau-20-1259.

Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.

Martinez V, Munera-Maravilla E, Bernardini A, Rubio C, Suarez-Cabrera C, Segovia C Front Genet. 2019; 10:1125.

PMID: 31850055 PMC: 6902278. DOI: 10.3389/fgene.2019.01125.

The current role of circulating biomarkers in non-muscle invasive bladder cancer.

Rink M, Schwarzenbach H, Vetterlein M, Riethdorf S, Soave A Transl Androl Urol. 2019; 8(1):61-75.

PMID: 30976570 PMC: 6414344. DOI: 10.21037/tau.2018.11.05.

Promoter DNA Methylation and mRNA Expression Level of p16 Gene in Oral Squamous Cell Carcinoma: Correlation with Clinicopathological Characteristics.

Allameh A, Moazeni-Roodi A, Harirchi I, Ravanshad M, Motiee-Langroudi M, Garajei A Pathol Oncol Res. 2018; 25(4):1535-1543.

PMID: 30511108 DOI: 10.1007/s12253-018-0542-1.

References

Esteller M, Corn P, Baylin S, Herman J . A gene hypermethylation profile of human cancer. Cancer Res. 2001; 61(8):3225-9. View

Poirier L . The effects of diet, genetics and chemicals on toxicity and aberrant DNA methylation: an introduction. J Nutr. 2002; 132(8 Suppl):2336S-2339S. DOI: 10.1093/jn/132.8.2336S. View

Chang L, Yeh W, Yang S, Wu W, Huang C . Genetic alterations of p16INK4a and p14ARF genes in human bladder cancer. J Urol. 2003; 170(2 Pt 1):595-600. DOI: 10.1097/01.ju.0000067626.37837.3e. View

Maruyama R, Toyooka S, Toyooka K, Harada K, Virmani A, Zochbauer-Muller S . Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 2001; 61(24):8659-63. View

Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin S, Herman J . Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 1999; 59(1):67-70. View

Herman J, Baylin S . Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003; 349(21):2042-54. DOI: 10.1056/NEJMra023075. View

Chan M, Chan L, Tang N, Tong J, Lo K, Lee T . Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res. 2002; 8(2):464-70. View

Singal R, van Wert J, Bashambu M . Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 2001; 61(12):4820-6. View

Fruhwald M, Plass C . Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Genet Metab. 2002; 75(1):1-16. DOI: 10.1006/mgme.2001.3265. View

10.

Velentza A, Schumacher A, Weiss C, Egli M, Watterson D . A protein kinase associated with apoptosis and tumor suppression: structure, activity, and discovery of peptide substrates. J Biol Chem. 2001; 276(42):38956-65. DOI: 10.1074/jbc.M104273200. View

11.

Yukawa K, Hoshino K, Kishino M, Mune M, Shirasawa N, Kimura A . Deletion of the kinase domain in death-associated protein kinase attenuates renal tubular cell apoptosis in chronic obstructive uropathy. Int J Mol Med. 2004; 13(4):515-20. View

12.

Dominguez G, Carballido J, Silva J, Silva J, Garcia J, Menendez J . p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res. 2002; 8(4):980-5. View

13.

Esteller M, Herman J . Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2001; 196(1):1-7. DOI: 10.1002/path.1024. View

14.

Herman J, Graff J, Myohanen S, Nelkin B, Baylin S . Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996; 93(18):9821-6. PMC: 38513. DOI: 10.1073/pnas.93.18.9821. View

15.

Brown I, Milner B, Rooney P, Haites N . Inactivation of the p16INK4A gene by methylation is not a frequent event in sporadic ovarian carcinoma. Oncol Rep. 2001; 8(6):1359-62. DOI: 10.3892/or.8.6.1359. View

16.

Bombail V, Moggs J, Orphanides G . Perturbation of epigenetic status by toxicants. Toxicol Lett. 2004; 149(1-3):51-8. DOI: 10.1016/j.toxlet.2004.01.003. View

17.

Nakagawa T, Kanai Y, Ushijima S, Kitamura T, Kakizoe T, Hirohashi S . DNA hypermethylation on multiple CpG islands associated with increased DNA methyltransferase DNMT1 protein expression during multistage urothelial carcinogenesis. J Urol. 2005; 173(5):1767-71. DOI: 10.1097/01.ju.0000154632.11824.4d. View

18.

Anker P, Stroun M . Tumor-related alterations in circulating DNA, potential for diagnosis, prognosis and detection of minimal residual disease. Leukemia. 2001; 15(2):289-91. DOI: 10.1038/sj.leu.2402016. View

19.

Wong I . Methylation profiling of human cancers in blood: molecular monitoring and prognostication (review). Int J Oncol. 2001; 19(6):1319-24. View

20.

Tada Y, Wada M, Taguchi K, Mochida Y, Kinugawa N, Tsuneyoshi M . The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 2002; 62(14):4048-53. View